Apimeds Pharmaceuticals US (APUS)

• Market cap: $17M
• 1 day: 3.85%
• 5 days: 6.3%
• 1 month: -11.76%
• 3 months: -35.71%
• 6 months: -33.17%
• Year to date: -19.16%
• 1 year: -38.64%
• 5 years: -38.64%
• 10 years: -38.64%
• Sector: Healthcare
• Industry: Drug Manufacturers - General

About: Apimeds Pharmaceuticals Us Inc is a clinical-stage company. It is engaged in a pharmaceutical business that provides the biological drug Apitox to clients in the biological drug commercial transaction area. It are a clinical stage biopharmaceutical company in the process of developing Apitox, an intradermally administered bee venom-based toxin. Company focus is on developing therapies that address inflammation and pain management symptoms associated with knee OA and, to a lesser extent, MS. Apitox is currently marketed and sold by Apimeds Inc. in South Korea as Apitoxin for the treatment of OA.

Employees: 2